Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002506 · ClinicalTrials.gov registry record · Phase 2
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002506 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian.
The verdict
NCT00002506, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of isotretinoin may be an effective way to prevent cancer or stop cancer from growing. Interferon alfa may interfere with the growth of cancer cells. Combining isotretinoin and interferon may be an effective treatment for some recurrent cancers. PURPOSE: Phase II trial to study the effectiveness of interferon alfa plus isotretinoin in treating patients with recurrent cancer.
Interventions
- BIOLOGICAL recombinant interferon alfa
- DRUG isotretinoin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-08 |
| Est. Completion | 1999-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002506
The ClinicalTrials.gov registry entry for NCT00002506 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant interferon alfa is the first listed.
NCT00002506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002506 about?
NCT00002506 is a clinical study titled "Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of isotretinoin may be an effective way to prevent cancer or stop cancer from growing. Interferon alfa may interfere with the growth of cancer cells. Combining isotretino...
What is the current status of trial NCT00002506?
This trial is currently completed. It is a Phase 2 study. The study started on 1992-08. Estimated completion is 1999-02.
What interventions are being tested in trial NCT00002506?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00002506?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.